A phase II study of CDK4/6 inhibition with palbociclib combined with programmed cell death protein 1 (PD-1) blockade (INCMGA00012) (NCT04438824) in patients with advanced WDLPS and/or DDLPS is underway. Here, CDK4 is linked to dedifferentiated liposarcoma.